Stock comparison
BioCryst Pharmaceuticals
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BCRX
BioCryst Pharmaceuticals
Market cap
$1.74B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BCRX | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 40D | 70B | HAE |
| Benjamin Graham | 24F | 85A | HAE |
| Philip Fisher | 40D | 60C | HAE |
| Peter Lynch | 60C | 54C | BCRX |
| Joel Greenblatt | 4F | 31F | HAE |
| Charlie Munger | 35D | 54D | HAE |
| Terry Smith | 41D | 55D | HAE |
Side-by-side metrics
| Metric | BCRX | HAE |
|---|---|---|
| Market cap | $1.74B | $2.98B |
| P/E (TTM) | - | 24.8x |
| EV/EBIT | 7.6x | 14.1x |
| ROIC (TTM) | -121.96% | 8.37% |
| Gross margin | 18.89% | 55.74% |
| Net margin | -51.71% | 7.29% |
| Revenue CAGR 5y | 53.6% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | - | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BCRX leads on
- Debt / Equity-vs 1.5x+199%
- P/E (TTM)-vs 24.8x+119%
- Revenue CAGR 5y53.6%vs 7.65%+86%
- EV/EBIT7.6xvs 14.1x+46%
HAE leads on
- Net margin7.29%vs -51.71%+114%
- ROIC (TTM)8.37%vs -121.96%+107%
- Gross margin55.74%vs 18.89%+66%
- Market cap$2.98Bvs $1.74B+42%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.